Archive · 2 Jun 2025
Mankind Pharma Aims for 26% Growth in FY26, Chronic Therapies to Drive
Mankind Pharma is aiming for big growth, around 26%, in the next year.
They're working hard on new medicines for things like diabetes and weight problems, with promising early results.
They plan to launch a new medicine called Semaglutide when the patent expires.
They're also expanding in women's health after buying another company.
Their existing products like Gas-O-Fast and Prega News are doing well in the market.
They also reduced their debt.
Mankind Pharma's focus is on increasing sales, especially for chronic diseases and OTC products.
Mankind Pharma aims for 26% growth in FY26, with chronic therapies and OTC products driving momentum.
The company is conducting phase 2 trials for a novel molecule targeting obesity and diabetes.
Mankind is planning a Semaglutide launch once the patent expires.
The company is strengthening its women’s health pipeline after acquiring Bharat Serums and Vaccines (BSV).
The company expects to fully repay its debt by FY27 or early FY28.
- Who
- Mankind Pharma
- What
- Mankind Pharma is targeting 26% growth in FY26.
- When
- FY26
- Where
- N/A
- Why
- Due to the expected growth in chronic therapies, OTC segment and contributions from the BSV portfolio.
- FY26 Growth Target
- 26%
- Chronic Therapies Revenue
- 37%
- OTC Segment Growth (FY25)
- 15%
- Debt-to-EBITDA Ratio
- 1.8x
- Domestic Business (FY25)
- ₹10,000 crore